HIV pre-exposure prophylaxis in US prison settings: a model-based cost-effectiveness study.
- 1Department of Epidemiology and Biostatistics, Schulich School of Medicine & Dentistry, Western University, London, ON, Canada.
- 2Department of Health Policy and Center for Health Policy, Stanford School of Medicine and Freeman Spogli Institute, Stanford University, Stanford, CA, USA.
- 3Ivey Business School and Departments of Epidemiology & Biostatistics and Medicine, Schulich School of Medicine & Dentistry, Western University, London, ON, Canada.
Abstract
Background
HIV prevalence in prisons is three times higher than in the general community, and ongoing transmission risks highlight the importance of prevention, including pre-exposure prophylaxis (PrEP). We evaluated the effectiveness and cost-effectiveness of prison-based PrEP programs in four US states.Methods
We developed a dynamic compartmental model simulating HIV transmission in both general and incarcerated populations, instantiated for four representative US states (standardized population of five million people). We assessed five strategies involving PrEP for specific risk groups in prison compared to the status quo of no PrEP. We assumed 25% uptake among eligible individuals for 20 years. We estimated total lifetime costs (in 2024 USD) and quality-adjusted life-years (QALYs), discounted at 3% annually, incremental cost-effectiveness ratios (ICERs), and HIV infections averted from a healthcare sector perspective.Findings
In Washington, New York, and Georgia, providing PrEP to 25% of people who inject drugs (PWID) in prison prevented 12%-14% of new infections in incarcerated people, and 0.01%-0.02% of new infections in the community, and was cost-saving compared to no PrEP. Expanding eligibility to all high-risk persons (PWID and men who have sex with men (MSM)) prevented more infections and cost less than $60,000 per QALY gained compared to more restrictive policies. In California, where the epidemic is concentrated among MSM rather than PWID, providing PrEP to only MSM costs $32,000 per QALY gained.Interpretation
Prison-based PrEP programs can be cost-saving or cost-effective, averting infections within and outside the prison system. These findings support expanding access to PrEP in prisons, with implementation and funding decisions guided by local HIV epidemiology.Funding
Canada Research Chairs Program, Natural Sciences and Engineering Research Council of Canada, National Institute on Drug Abuse.
Related
- Comparing the cost-effectiveness of alternative policies for recommending and providing HIV pre-exposure prophylaxis to men who have sex with men in the EU
- Cost-Effectiveness of Ensitrelvir for COVID-19 Post-Exposure Prophylaxis Among High-Risk Household Contacts in Japan: A Model-Based Cost-Utility Analysis
- Cost-Effectiveness of Sulbactam-durlobactam Compared with Colistin for Treating Carbapenem-Resistant Acinetobacter baumannii Infections in Critical Care Settings in the United States
- Cost-effectiveness of malaria prevention strategies in children under five in high-endemic settings
- Evaluating the impact and cost-effectiveness of typhoid conjugate vaccine schedules across diverse settings: A multi-model comparison
BibTeX
@article{park2026preexposure,
title = {{HIV pre-exposure prophylaxis in US prison settings: a model-based cost-effectiveness study.}},
author = {Yhesaem Park and Jeremy D Goldhaber-Fiebert and Lauren E Cipriano},
journal = {Lancet regional health. Americas},
year = {2026},
month = oct,
doi = {10.1016/j.lana.2026.101652},
url = {https://europepmc.org/article/MED/42921453},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - HIV pre-exposure prophylaxis in US prison settings: a model-based cost-effectiveness study.
AU - Yhesaem Park
AU - Jeremy D Goldhaber-Fiebert
AU - Lauren E Cipriano
PY - 2026
DA - 2026/10/15
JO - Lancet regional health. Americas
DO - 10.1016/j.lana.2026.101652
UR - https://europepmc.org/article/MED/42921453
AB - Background HIV prevalence in prisons is three times higher than in the general community, and ongoing transmission risks highlight the importance of prevention, including pre-exposure prophylaxis (PrEP). We evaluated the effectiveness and cost-effectiveness of prison-based PrEP programs in four US states.Methods We developed a dynamic compartmental model simulating HIV transmission in both general and incarcerated populations, instantiated for four representative US states (standardized population of five million people). We assessed five strategies involving PrEP for specific risk groups in prison compared to the status quo of no PrEP. We assumed 25% uptake among eligible individuals for 20 years. We estimated total lifetime costs (in 2024 USD) and quality-adjusted life-years (QALYs), discounted at 3% annually, incremental cost-effectiveness ratios (ICERs), and HIV infections averted from a healthcare sector perspective.Findings In Washington, New York, and Georgia, providing PrEP to 25% of people who inject drugs (PWID) in prison prevented 12%-14% of new infections in incarcerated people, and 0.01%-0.02% of new infections in the community, and was cost-saving compared to no PrEP. Expanding eligibility to all high-risk persons (PWID and men who have sex with men (MSM)) prevented more infections and cost less than $60,000 per QALY gained compared to more restrictive policies. In California, where the epidemic is concentrated among MSM rather than PWID, providing PrEP to only MSM costs $32,000 per QALY gained.Interpretation Prison-based PrEP programs can be cost-saving or cost-effective, averting infections within and outside the prison system. These findings support expanding access to PrEP in prisons, with implementation and funding decisions guided by local HIV epidemiology.Funding Canada Research Chairs Program, Natural Sciences and Engineering Research Council of Canada, National Institute on Drug Abuse.
SN - 2667-193X
ER -